Key takeaways:
Spiriva (tiotropium) is a daily inhaler medication that’s FDA-approved to treat chronic obstructive pulmonary disease (COPD).
Spiriva comes in two types of inhalers, Spiriva HandiHaler and Spiriva Respimat. Although the two inhalers deliver the medication differently, they both work well to treat COPD.
Spiriva may be a first-choice treatment for some people. Your healthcare provider can help determine if Spiriva is the right treatment for you.
There are several ways to save on Spiriva. Manufacturer savings cards and patient assistance programs are available. GoodRx can also help you access the generic version, tiotropium, at exclusive cash prices.
Chronic obstructive pulmonary disease (COPD) is a common condition that affects more than 15 million adults in the U.S. It’s also the fourth-leading cause of death in the country.
There are several inhalers and other medications that treat the condition. One of those is Spiriva (tiotropium),, a once-daily inhaled prescription medication that is FDA-approved to treat COPD.
Spiriva is a long-acting, inhaled anticholinergic medication that opens up the airways. Spiriva is available as the Spiriva HandiHaler (tiotropium bromide capsule) and the Spiriva Respimat Inhaler (tiotropium bromide inhalation spray). The Spiriva HandiHaler is a dry powder preparation that’s used in a capsule-based inhaler. The dosage is 2 inhalations of a single 18 mcg capsule once daily. The Spiriva Respimat Inhaler is a soft mist inhaler administered as 2inhalations of 2.5 mcg (5 mcg total) once daily.
As mentioned above, Spiriva Respimat and Spiriva HandiHaler are two different types of Spiriva inhalers. While the inhalers are quite different, they both about the same in terms of safety and effectiveness.
The Spiriva HandiHaler was the first of the two inhaler forms to come on the market and was approved by the FDA in 2004 With the HandiHaler, you take a capsule of powdered medication and place it into the inhaler chamber. Then, you press a button on the side of the inhaler to pierce the capsule and you breathe in the medication. You do not swallow the capsule.
The Spiriva Respimat Inhaler was approved by the FDA in 2014. The medication used with the Respimat Inhaler is a fine mist, kind of like what you would use with a nebulizer. You twist the inhaler to load the dose, then remove the cap, and inhale while pressing a button that delivers the medication. The Respimat Inhaler is also approved to treat asthma in people ages 6 and older, whereas the HandiHaler is just approved for the treatment of COPD.
Another difference between these two versions of Spiriva is the inhaler device in which they are supplied. The research shows that they work about the same to help with COPD, so choosing between them may come down to which one you’re most comfortable with . If you’re using the Spiriva HandiHaler or the Spiriva Respimat Inhaler, make sure to check with your healthcare provider or pharmacist on how to administer the medication properly.
Spiriva works to relax the airways and make it easier to breathe for people who have COPD. It targets muscarinic receptors in the airways and lowers the action of the neurotransmitter acetylcholine, which regulates muscle contraction and other bodily functions, at these receptors. In addition to relaxing muscles in the airways, it helps lower the amount of mucus, or secretions, in the lungs.
No, Spiriva is not a steroid. Spiriva is a long-acting anticholinergic medication. It’s also referred to as a long-acting muscarinic antagonist (LAMA) medication.
It acts on chemical receptors (binding sites) in the airways to relax the muscles and increase airflow. This is different from how steroid medications work. Though, inhaled corticosteroids are commonly used to treat asthma and COPD.
Research shows that Spiriva and other inhaled anticholinergic medications can have many benefits for people with COPD.
Some of these benefits include:
Improvement in COPD symptoms
Better health status in general
More effective pulmonary rehabilitation efforts
Less exacerbations
Fewer hospitalizations
Like with all medications, Spiriva can cause side effects. Common side effects include:
Although rare, Spiriva can also cause serious side effects. Severe allergic reactions (anaphylaxis), trouble urinating, and worsened glaucoma have been reported with the medication.
Another serious side effect is a paradoxical bronchospasm, which causes difficulty breathing or a sudden worsening of wheezing. If this happens, you should use a rescue inhaler like albuterol (Ventolin, ProAir, Proventil). And, if the symptoms continue or get worse, you should seek emergency medical care.
Yes, Spiriva is meant to be used as a daily, long-term maintenance inhaler. In one study that observed patients with COPD for 4 years, Spiriva improved overall lung function.
Spiriva is longer-acting than Atrovent (ipratropium), another daily inhaler approved to treat COPD. Because it’s short-acting, Atrovent usually needs to be taken 4 times a day. In a review of studies comparing both medications, taking Spiriva resulted in better lung function, less hospitalizations, less exacerbations, and better quality of life.
Once-daily Spiriva has been compared to Serevent (salmeterol), which is also a long-acting inhaler medication. One study found that Spiriva was more effective than Severent at preventing exacerbations in people with moderate to severe COPD.
Symbicort (budesonide/formoterol) is a combination medication. In one study, participants starting treatment with an inhaler for COPD had better health improvements from taking Symbicort than from taking Spiriva. But, since these two inhalers work in different ways, they can be combined to treat COPD if your symptoms aren’t well controlled, which is sometimes called step-up treatment.
Spiriva may be a first-choice treatment for your COPD , depending on your symptoms and your health history. Your healthcare provider can help you determine the best treatment to start with.
Once you begin treatment, your healthcare provider will also help monitor how well the medication is working. If your symptoms are getting worse, you may need a higher dose or different medication to manage your condition.
There are ways to save on Spiriva, which is available as a brand-name and generic medication. GoodRx can help you navigate between GoodRx coupons, copay savings cards, and patient assistance programs to save money on your prescription.
Save with GoodRx: Anyone with a valid prescription, regardless of insurance status, can use GoodRx to purchase a 30-day supply of generic tiotropium at an exclusive cash price, which ranges from $75 to $365 — prices vary by pharmacy.
Save with a copay savings card: If you have commercial insurance, you may be eligible to pay as little as $35 for Spiriva HandiHaler or Sprivia Respimat using a savings card from the manufacturer. A $25 savings card is available for the generic version of Spiriva HandiHaler, too.
Save with patient assistance programs: If you’re uninsured or underinsured, you may be eligible for Spiriva’s patient assistance program, which offers the medication free of charge.
Spiriva is a daily inhaler medication that helps control chronic obstructive pulmonary disease (COPD) and can result in fewer exacerbations and less hospitalizations. Spiriva comes in the HandiHaler and Respimat Inhaler. Although these devices deliver the medication differently, research has shown that they are equally effective at treating COPD.
Common side effects of Spiriva include dry mouth, cough, and sore throat. It may be a first-choice medication to treat COPD, but sometimes it’s added on later. If you have questions or concerns about using Spiriva for COPD, check with your healthcare provider.
Boehringer Ingelheim. (2014). Boehringer Ingelheim announces FDA approval of Spiriva® Respimat® (tiotropium bromide) inhalation spray for the maintenance treatment of COPD.
Boehringer Ingelheim Pharmaceuticals, Inc. (2021). Spiriva HandiHaler [package insert].
Boehringer Ingelheim Pharmaceuticals, Inc. (2021). Spiriva Respimat [package insert].
Cheyne, L., et al. (2013). Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews.
Global Initiative for Chronic Obstructive Lung Disease. (2022). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
National Heart, Lung, and Blood Institute. (2022). What is COPD?
Tashkin, D. P., et al. (2008). A 4-year trial of tiotropium in chronic obstructive pulmonary disease. The New England Journal of Medicine.
Trudo, F., et al. (2015). Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. International Journal of Chronic Obstructive Pulmonary Disease.
Vogelmeier, C., et al. (2011). Tiotropium versus salmeterol for the prevention of exacerbations of COPD. The New England Journal of Medicine.
Wise, R. A., et al. (2013). Tiotropium Respimat inhaler and the risk of death in COPD. The New England Journal of Medicine.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.